Literature DB >> 25897354

Diabetic neuropathic pain: Physiopathology and treatment.

Anne K Schreiber1, Carina Fm Nones1, Renata C Reis1, Juliana G Chichorro1, Joice M Cunha1.   

Abstract

Diabetic neuropathy is a common complication of both type 1 and type 2 diabetes, which affects over 90% of the diabetic patients. Although pain is one of the main symptoms of diabetic neuropathy, its pathophysiological mechanisms are not yet fully known. It is widely accepted that the toxic effects of hyperglycemia play an important role in the development of this complication, but several other hypotheses have been postulated. The management of diabetic neuropathic pain consists basically in excluding other causes of painful peripheral neuropathy, improving glycemic control as a prophylactic therapy and using medications to alleviate pain. First line drugs for pain relief include anticonvulsants, such as pregabalin and gabapentin and antidepressants, especially those that act to inhibit the reuptake of serotonin and noradrenaline. In addition, there is experimental and clinical evidence that opioids can be helpful in pain control, mainly if associated with first line drugs. Other agents, including for topical application, such as capsaicin cream and lidocaine patches, have also been proposed to be useful as adjuvants in the control of diabetic neuropathic pain, but the clinical evidence is insufficient to support their use. In conclusion, a better understanding of the mechanisms underlying diabetic neuropathic pain will contribute to the search of new therapies, but also to the improvement of the guidelines to optimize pain control with the drugs currently available.

Entities:  

Keywords:  Anticonvulsants; Antidepressants; Diabetes; Hyperglycemia; Neuropathic pain

Year:  2015        PMID: 25897354      PMCID: PMC4398900          DOI: 10.4239/wjd.v6.i3.432

Source DB:  PubMed          Journal:  World J Diabetes        ISSN: 1948-9358


  175 in total

1.  The GABAB1b isoform mediates long-lasting inhibition of dendritic Ca2+ spikes in layer 5 somatosensory pyramidal neurons.

Authors:  Enrique Pérez-Garci; Martin Gassmann; Bernhard Bettler; Matthew E Larkum
Journal:  Neuron       Date:  2006-05-18       Impact factor: 17.173

2.  Drugs for neuropathic pain.

Authors:  Eija Kalso; D J Aldington; R A Moore
Journal:  BMJ       Date:  2013-12-19

3.  Impact of comorbidities on pharmacotherapy of painful diabetic neuropathy in clinical practice.

Authors:  Dan Ziegler; Edith Schneider; Frank G Boess; Lovisa Berggren; Frank Birklein
Journal:  J Diabetes Complications       Date:  2014-04-18       Impact factor: 2.852

4.  Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats.

Authors:  Shao-Rui Chen; Hui-Lin Pan
Journal:  J Neurophysiol       Date:  2002-06       Impact factor: 2.714

5.  Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states.

Authors:  M S Bitar; K T Bajic; T Farook; M I Thomas; C W Pilcher
Journal:  Brain Res       Date:  1999-05-29       Impact factor: 3.252

6.  Comparison of metabolic and neuropathy profiles of rats with streptozotocin-induced overt and moderate insulinopenia.

Authors:  D Romanovsky; J Wang; E D Al-Chaer; J R Stimers; M Dobretsov
Journal:  Neuroscience       Date:  2010-07-01       Impact factor: 3.590

7.  A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin.

Authors:  Che S Zin; Lisa M Nissen; James P O'Callaghan; Stephen B Duffull; Maree T Smith; Brendan J Moore
Journal:  J Pain       Date:  2009-12-03       Impact factor: 5.820

Review 8.  Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis.

Authors:  S Guy; S Mehta; L Leff; R Teasell; E Loh
Journal:  Spinal Cord       Date:  2013-12-03       Impact factor: 2.772

9.  A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.

Authors:  Viktor R Drel; Pal Pacher; Igor Vareniuk; Ivan Pavlov; Olga Ilnytska; Valeriy V Lyzogubov; Jyoti Tibrewala; John T Groves; Irina G Obrosova
Journal:  Eur J Pharmacol       Date:  2007-06-09       Impact factor: 4.432

10.  A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy.

Authors:  Niral Patel; Vishal Mishra; Prakruti Patel; Ram K Dikshit
Journal:  J Diabetes Metab Disord       Date:  2014-05-27
View more
  90 in total

1.  Cutaneous Aβ-Non-nociceptive, but Not C-Nociceptive, Dorsal Root Ganglion Neurons Exhibit Spontaneous Activity in the Streptozotocin Rat Model of Painful Diabetic Neuropathy in vivo.

Authors:  Laiche Djouhri; Asad Zeidan; Seham A Abd El-Aleem; Trevor Smith
Journal:  Front Neurosci       Date:  2020-05-25       Impact factor: 4.677

Review 2.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

3.  Effect of photobiomodulation on mitochondrial dynamics in peripheral nervous system in streptozotocin-induced type 1 diabetes in rats.

Authors:  Igor Rafael Correia Rocha; Edward Perez-Reyes; Marucia Chacur
Journal:  Photochem Photobiol Sci       Date:  2021-02-18       Impact factor: 3.982

4.  Antinociceptive interaction of gabapentin with minocycline in murine diabetic neuropathy.

Authors:  H F Miranda; F Sierralta; V Jorquera; P Poblete; J C Prieto; V Noriega
Journal:  Inflammopharmacology       Date:  2017-02-28       Impact factor: 4.473

5.  Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.

Authors:  Geraldine F Clough; Keith G McCormick; Eleonora Scorletti; Lokpal Bhatia; Philip C Calder; Michael J Griffin; Christopher D Byrne
Journal:  Diabetologia       Date:  2016-04-22       Impact factor: 10.122

6.  A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.

Authors:  Boris Tabakoff; Wenhua Ren; Lauren Vanderlinden; Lawrence D Snell; Christopher J Matheson; Ze-Jun Wang; Rock Levinson; C Thetford Smothers; John J Woodward; Yumiko Honse; David Lovinger; Anthony M Rush; William A Sather; Daniel L Gustafson; Paula L Hoffman
Journal:  Eur J Pharmacol       Date:  2016-05-05       Impact factor: 4.432

7.  Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia.

Authors:  Lin Li; Xuan Sheng; Shanhong Zhao; Lifang Zou; Xinyao Han; Yingxin Gong; Huilong Yuan; Liran Shi; Lili Guo; Tianyu Jia; Shuangmei Liu; Bing Wu; Zhihua Yi; Hui Liu; Yun Gao; Guilin Li; Guodong Li; Chunping Zhang; Hong Xu; Shangdong Liang
Journal:  Purinergic Signal       Date:  2017-08-24       Impact factor: 3.765

8.  Modulatory effects of photobiomodulation in the anterior cingulate cortex of diabetic rats.

Authors:  Igor Rafael Correia Rocha; Marucia Chacur
Journal:  Photochem Photobiol Sci       Date:  2021-05-30       Impact factor: 3.982

9.  Luteolin improves the impaired nerve functions in diabetic neuropathy: behavioral and biochemical evidences.

Authors:  Ming Li; Qiang Li; Qingsong Zhao; Jinchao Zhang; Jiang Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  lncRNA NONRATT021972 siRNA Decreases Diabetic Neuropathic Pain Mediated by the P2X3 Receptor in Dorsal Root Ganglia.

Authors:  Haiying Peng; Lifang Zou; Jinyan Xie; Hong Wu; Bing Wu; Gaochun Zhu; Qiulan Lv; Xi Zhang; Shuangmei Liu; Guilin Li; Hong Xu; Yun Gao; Changshui Xu; Chunping Zhang; Shouyu Wang; Yun Xue; Shangdong Liang
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.